Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443918 | 1.00 | CTSB (0.57) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8331508 | 0.96 | CTSB (0.54) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8332535 | 0.94 | PSEN1 (0.53) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8331942 | 0.94 | PSEN1 (0.51) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6557017 | 0.93 | CTSB (0.54) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5929888 | 0.93 | CTSB (0.54) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5929911 | 0.93 | CTSB (0.54) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3545793 | 0.91 | PSEN1 (0.49) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7336056 | 0.91 | CYP3A4 (0.54) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8331011 | 0.90 | PSEN1 (0.52) | CTSBPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0633881-B1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LTD (HK) | 2003-10-29 | — | — | EP | claimed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-20040266871-A1 | Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons | PHARMACIA & UPJOHN | 2004-12-30 | — | — | US | disclosed |
| EP-0633881-B1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LTD (HK) | 2003-10-29 | — | — | EP | disclosed |
| US-6258806-B1 | PEPTIDES WITH CYCLIC DIAZAALKANES FOR PREVENTION OF PREMATURE METABOLISM METHOD FOR INHIBITING AN HIV PROTEASE IN A MAMMAL IN NEED OF SUCH PROTEASE INHIBITION, COMPRISING ADMINISTERING TO SAID MAMMAL AN EFFECTIVE DOSAGE | NARHEX LIMITED (HK) | 2001-07-10 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0633881-A4 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS. | — | 1995-02-22 | — | — | EP | disclosed |
| EP-0633881-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | Narhex Limited (HK) | 1995-01-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993018006-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LIMITED (HK) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CTSB 41/4885PSEN1 2/4885PSEN2 5/4885 |
| US-20040266871-A1 | Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons | BACE1, BACE2, PSEN1 | CTSB 67/4885PSEN1 3/4885PSEN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.